# Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)

> **NCT00488982** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 125 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Docetaxel and GM-CSF

## Key facts

- **NCT ID:** NCT00488982
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2014-03
- **Final completion:** 2014-05
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2019-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00488982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00488982, "Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00488982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*